{"metadata": {"source": "pubchem", "title": "Psilocybin | C12H17N2O4P | CID 10624 - PubChem", "description": "Psilocybin | C12H17N2O4P | CID 10624 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/10624", "drug": "Psilocybin", "cid": 10624, "char_count": 52378, "word_count": 6471, "doc_id": "doc_62", "num_chunks": 72, "chunk_id": "62::chunk_64", "document_index": 62, "latency_s": 1.0541961999988416, "prompt_toks": 15270, "completion_toks": 82, "relevance_score": 0.0007069056}, "content": "Drug: Psilocybin | cid: 10624\nSource: pubchem | Source description: Psilocybin | C12H17N2O4P | CID 10624 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Psilocybine (EU/3/21/2513)\n\nhttps://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2513\n\nHaz-Map, Information on Hazardous Chemicals and Occupational Diseases\n\nLICENSE\n\nCopyright (c) 2022 Haz-Map(R). All rights reserved. Unless otherwise indicated, all materials from Haz-Map are copyrighted by Haz-Map(R). No part of these materials, either text or image may be used for any purpose other than for personal use. Therefore, reproduction, modification, storage in a retrieval system or retransmission, in any form or by any means, electronic, mechanical or otherwise, for reasons other than personal use, is strictly prohibited without prior written permission.\n\nhttps://haz-map.com/About\n\nPsilocybine\n\nhttps://haz-map.com/Agents/6898\n\nHuman Metabolome Database (HMDB)\n\nLICENSE\n\n\n                    Context: \n                    This segment provides regulatory and hazard information for Psilocybine under EU orphan designation (EU/3/21/2513), including a link to EMA’s classification. It also covers Haz-Map licensing details and references the Human Metabolome Database (HMDB) license, situating it within the broader context of chemical safety, regulatory status, and biomedical data related to psilocybin compounds.\n                "}
{"metadata": {"source": "pubchem", "title": "Morphine | C17H19NO3 | CID 5288826 - PubChem", "description": "Morphine | C17H19NO3 | CID 5288826 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5288826", "drug": "Morphine", "cid": 5288826, "char_count": 201355, "word_count": 27013, "doc_id": "doc_53", "num_chunks": 298, "chunk_id": "53::chunk_134", "document_index": 53, "latency_s": 1.3172991999890655, "prompt_toks": 53666, "completion_toks": 101, "relevance_score": 0.00030534892}, "content": "Drug: Morphine | cid: 5288826\nSource: pubchem | Source description: Morphine | C17H19NO3 | CID 5288826 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    A study of pregnant women being treated for opiate dependency with slow-release oral morphine at a clinic in Vienna were followed as were their newborn infants. Compared to infants who were not breastfed (n = 91), breastfed infants (n = 21) had lower average measures of neonatal abstinence, lower dosage requirements of morphine (5.23 mg vs 8.75 mg), shorter durations of treatment for neonatal abstinence (10.2 vs 18.1 days) and shorter hospital stays (19.7 vs 31 days).\n\n\n                    Context: \n                    This excerpt relates to the section on neonatal and maternal exposure to morphine, specifically highlighting research on pregnant women treated with oral morphine for opiate dependency in Vienna and their infants' outcomes. It provides data on lower neonatal abstinence measures, reduced morphine dosages, shorter treatment durations, and reduced hospital stays in breastfed infants compared to non-breastfed, emphasizing the implications for opioid use during pregnancy and breastfeeding within the broader discussion on morphine's effects on pregnancy and neonatal health.\n                "}
{"metadata": {"source": "psychonaut", "title": "Gabapentin - PsychonautWiki", "description": "Gabapentin (also known as Neurontin) is a depressant substance of the gabapentinoid class. It is a structural analog of the neurotransmitter GABA and acts by inhibiting certain calcium channels in the brain, namely α2δ subunit-containing voltage-dependent calcium channels (VGCCs).[3]", "language": "en-GB", "url": "https://m.psychonautwiki.org/wiki/Gabapentin", "drug": "Gabapentin", "cid": 3446, "char_count": 21536, "word_count": 3003, "doc_id": "doc_91", "num_chunks": 30, "chunk_id": "91::chunk_29", "document_index": 91, "latency_s": 0.6145106999902055, "prompt_toks": 5756, "completion_toks": 74, "relevance_score": 0.00023782204}, "content": "Drug: Gabapentin | cid: 3446\nSource: psychonaut | Source description: Gabapentin (also known as Neurontin) is a depressant substance of the gabapentinoid class. It is a structural analog of the neurotransmitter GABA and acts by inhibiting certain calcium channels in the brain, namely α2δ subunit-containing voltage-dependent calcium channels (VGCCs).[3]\n\n                    Text: \n                    ↑ Collins, S. (October 2021). \"More states make gabapentin a Schedule V Controlled Substance\". Pharmacy Today. 27 (10): 33. doi:10.1016/j.ptdy.2021.09.016. ISSN 1042-0991.\n\nRetrieved from ‘https://psychonautwiki.org/w/index.php?title=Gabapentin&oldid=165648’\n\n\n                    Context: \n                    This reference summarizes legal changes in the U.S. as of October 2021, noting that additional states classified gabapentin as a Schedule V controlled substance. It is part of the broader legal status section of the document, which details prescription regulations and legal classifications of gabapentin across different regions. This citation provides recent regulatory context relevant to legal considerations and harm reduction.\n                "}
